Abstract
The limited distribution of lipoprotein (a) (Lp(a)) to humans, Old World primates and to the European hedgehog, has raised considerable interest and speculation regarding its possible physiological role. Lp(a) has variable circulating concentrations (<0.1 – >100 mg/ml) which are highly genetically determined in humans. These characteristics gave rise to several theories concerning the origins and evolution of Lp(a). Lp(a) has a protective role after injury since Lp(a) particles bind to macrophages and platelets membrane receptors, leading to fibrin activation and injury healing. On the other hand, Lp(a) seems to be implicated in the formation of atheromatic plaques but also in cerebrovascular events and stenosis of the aortic valve.
The main genetic factor determining plasma Lp(a) levels is the Lp(a) gene (LPA). Most Caucasian people have normal plasma Lp(a) concentrations, but there is important distribution variation according to race. Women seem to have increased Lp(a) levels compared with men, while diabetes mellitus type 2 favours lower plasma Lp(a) levels. Nutrition, hormones and several drugs may also influence circulating Lp(a) levels.Keywords: Lipoprotein (a), evolution, genetic factor, race, gender, hormones, drugs.
Current Medicinal Chemistry
Title:Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels
Volume: 24 Issue: 10
Author(s): Peggy M. Kostakou, George Hatzigeorgiou, Vana Kolovou, Sophie Mavrogeni and Genovefa D. Kolovou*
Affiliation:
- Outpatient Clinics and LDL Apheresis Unit, Onassis Cardiac Surgery Center, 356 Sygrou Ave 176 74, Athens,Greece
Keywords: Lipoprotein (a), evolution, genetic factor, race, gender, hormones, drugs.
Abstract: The limited distribution of lipoprotein (a) (Lp(a)) to humans, Old World primates and to the European hedgehog, has raised considerable interest and speculation regarding its possible physiological role. Lp(a) has variable circulating concentrations (<0.1 – >100 mg/ml) which are highly genetically determined in humans. These characteristics gave rise to several theories concerning the origins and evolution of Lp(a). Lp(a) has a protective role after injury since Lp(a) particles bind to macrophages and platelets membrane receptors, leading to fibrin activation and injury healing. On the other hand, Lp(a) seems to be implicated in the formation of atheromatic plaques but also in cerebrovascular events and stenosis of the aortic valve.
The main genetic factor determining plasma Lp(a) levels is the Lp(a) gene (LPA). Most Caucasian people have normal plasma Lp(a) concentrations, but there is important distribution variation according to race. Women seem to have increased Lp(a) levels compared with men, while diabetes mellitus type 2 favours lower plasma Lp(a) levels. Nutrition, hormones and several drugs may also influence circulating Lp(a) levels.Export Options
About this article
Cite this article as:
Kostakou M. Peggy, Hatzigeorgiou George, Kolovou Vana, Mavrogeni Sophie and Kolovou D. Genovefa*, Lipoprotein (a) Evolution: Possible Benefits and Harm. Genetic and Non-Genetic Factors Influencing its Plasma Levels, Current Medicinal Chemistry 2017; 24 (10) . https://dx.doi.org/10.2174/0929867324666170120155412
DOI https://dx.doi.org/10.2174/0929867324666170120155412 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antihyperglycemic Potential of Incretins Orally Delivered via Nano and Microsystems and Subsequent Glucoregulatory Effects
Current Pharmaceutical Biotechnology Artificial Intelligence, Big Data and Machine Learning Approaches in Precision Medicine & Drug Discovery
Current Drug Targets Metabolic Syndrome Racial Differences in Adolescents
Current Diabetes Reviews Meet Our Section Editor
Current Diabetes Reviews The Effects of Obesity on Drug Metabolism in Children
Drug Metabolism Letters High-dose Cholecalciferol Supplementation Reducing Morning Blood Pressure in Normotensive DM1 Patients
Current Diabetes Reviews Valproic Acid As Anti-Cancer Drug
Current Pharmaceutical Design Editorial [Hot Topic: Adrenergic Receptors as Novel Targets for Cancer Therapy (Guest Editors: D.G. Powe and F. Entschladen)]
Current Cancer Therapy Reviews Coronary Calcium Risk Score and Cardiovascular Risk
Current Vascular Pharmacology Genetic Basis, Nutritional Challenges and Adaptive Responses in the Prenatal Origin of Obesity and Type-2 Diabetes
Current Diabetes Reviews Transplacental Transfer of Antiretroviral Drugs and Newborn Birth Weight in HIV-Infected Pregnant Women
Current HIV Research Aldose Reductase / Polyol Inhibitors for Diabetic Retinopathy
Current Pharmaceutical Biotechnology Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Current Neuropharmacology A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) A Review of Intrahepatic Cholestasis of Pregnancy
Current Women`s Health Reviews Neurodegeneration in the Pathogenesis of Diabetic Retinopathy: Molecular Mechanisms and Therapeutic Implications
Current Medicinal Chemistry Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Calcitriol Reduces Hepatic Triglyceride Accumulation and Glucose Output Through Ca2+/CaMKKβ/AMPK Activation Under Insulin-Resistant Conditions in Type 2 Diabetes Mellitus
Current Molecular Medicine The Role of Vitamin D in Dyslipidemia and Cardiovascular Disease
Current Pharmaceutical Design Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design